Company: PSTV
Filing Date: 2025-04-30
Form Type: 10-K/A
Source: 0000950170-25-061028
Chunk: 27

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-30
Form: 10-K/A
Chunk 27
---
 options that are currently exercisable and unvested options to purchase shares of common stock held by Dr. van Es-Johansson that will vest within 60 days of April 18, 2025. Dr. van Es-Johansson is a director of Plus Therapeutics. (10) Reflects (i) 11,188 shares of common stock; (ii) 4,902 shares of common stock issuable upon the exercise of May 2024 Series A Warrants; (iii) 4,902 shares of common stock issuable upon the exercise of May 2024 Series B Warrants; and (iv) 22,127 shares of common stock underlying options that are currently exercisable and unvested options to purchase shares of common stock held by Mr. Hawkins that will vest within 60 days of April 18, 2025. Mr. Hawkins is the Chairman of the Board of Plus Therapeutics. (11) Reflects (i) 29,327 shares of common stock; (ii) 4,167 shares of common stock issuable upon the exercise of May 2024 Series A Warrants; (iii) 4,167 shares of common stock issuable upon the exercise of May 2024 Series B Warrants; and (iv) 19,455 shares of common stock underlying options that are currently exercisable and unvested options to purchase shares of common stock held by Dr. Lenk that will vest within 60 days of April 18, 2025. Dr. Lenk is a director of Plus Therapeutics. (12) Dr. LaFrance is our former Chief Medical Officer. The beneficial ownership information for Dr. LaFrance is based on information maintained by the Company. Equity Compensation Plan Information The following table gives information as of December 31, 2024 about shares of our common stock that may be issued upon the exercise of outstanding options, warrants and rights and shares remaining available for issuance under all of our equity compensation plans:

| Plan Category                                                 |     | Number of securities 
 to be issued upon    
 exercise of          
 outstanding options, 
 warrants and rights  
 (a)                  |         |     | Weighted-average     
 exercise price of    
 outstanding options, 
 warrants and rights  
 (b)                  |       |     | Number of securities    
 remaining available for 
 future issuance under   
 equity compensation     
 plans (excluding        
 securities reflected in 
 column(a)) (c)          |         |
|:--------------------------------------------------------------|:----|:----------------